AUTHOR=Xu Ling , Liu Lian , Yao Danlin , Zeng Xiangbo , Zhang Yikai , Lai Jing , Zhong Jun , Zha Xianfeng , Zheng Runhui , Lu Yuhong , Li Minming , Jin Zhenyi , Hebbar Subramanyam Sudheendra , Chen Shaohua , Huang Xin , Li Yangqiu TITLE=PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.686156 DOI=10.3389/fonc.2021.686156 ISSN=2234-943X ABSTRACT=
Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers, evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone marrow (BM) environment, the primary leukemia site, and peripheral blood (PB) and understanding how T cells are affected by AML induction chemotherapy or the influence of age may help to select patients who may benefit from ICI treatment. In this study, we comprehensively compared the distribution of PD-1 and TIGIT, two of the most well-studied IC proteins, in PB and BM T cells from AML patients at the stages of initial diagnosis, complete remission (CR), and relapse-refractory (R/R) disease after chemotherapy. Our results show that PD-1 was generally expressed higher in PB and BM T cells from